Compare · BLFS vs MDT
BLFS vs MDT
Side-by-side comparison of BioLife Solutions Inc. (BLFS) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLFS and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $106.50B, about 74.8x BLFS ($1.42B).
- Over the past year, BLFS is up 40.2% and MDT is down 7.3% - BLFS leads by 47.4 points.
- BLFS has been more active in the news (3 items in the past 4 weeks vs 2 for MDT).
- MDT has more recent analyst coverage (25 ratings vs 8 for BLFS).
- Company
- BioLife Solutions Inc.
- Medtronic plc.
- Price
- $29.11-3.83%
- $83.19-0.41%
- Market cap
- $1.42B
- $106.50B
- 1M return
- +10.60%
- +2.28%
- 1Y return
- +40.15%
- -7.27%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 2
- Recent ratings
- 8
- 25
BioLife Solutions Inc.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; liquid nitrogen laboratory freezers, cryogenic equipment, and accessories; and biological and pharmaceutical storage services. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest BLFS
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 844 shares, decreasing direct ownership by 0.39% to 213,249 units (SEC Form 4) (withholding obligation)
- EVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 516 shares, decreasing direct ownership by 0.13% to 388,460 units (SEC Form 4) (for tax liability)
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 293 shares, decreasing direct ownership by 0.18% to 162,649 units (SEC Form 4) to cover taxes
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 470 shares, decreasing direct ownership by 0.29% to 162,942 units (SEC Form 4) (tax liability)
- Chief Technology Officer Werner Sean covered exercise/tax liability with 420 shares, decreasing direct ownership by 0.87% to 47,831 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 937 shares, decreasing direct ownership by 0.44% to 214,093 units (SEC Form 4) to cover taxes
- EVP & Chief Scientific Officer Mathew Aby J. covered exercise/tax liability with 564 shares, decreasing direct ownership by 0.14% to 388,976 units (SEC Form 4) to cover taxes
- President and CEO De Greef Roderick covered exercise/tax liability with 2,775 shares, decreasing direct ownership by 0.38% to 730,971 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Wichterman Troy covered exercise/tax liability with 1,026 shares, decreasing direct ownership by 0.47% to 215,030 units (SEC Form 4) (withholding obligation)
- Chief Marketing Officer Berard Todd covered exercise/tax liability with 356 shares, decreasing direct ownership by 0.22% to 163,412 units (SEC Form 4) (tax withholding)
Latest MDT
- Medtronic completes acquisition of SPR, expanding patient access to minimally invasive, non-opioid treatment of chronic and acute pain
- SVP, Chief HR Officer Walter Matthew R. sold $257,931 worth of Ordinary Shares (3,102 units at $83.15), decreasing direct ownership by 8% to 35,694 units (SEC Form 4)
- New insider Thompson Kweli claimed ownership of 30,018 units of Ordinary Shares (SEC Form 3)
- SEC Form IRANNOTICE filed by Medtronic plc.
- SEC Form 10-K filed by Medtronic plc.
- Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)